The health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives of the
bill—and calling for further government efforts to help pharmaceutical research and development.
Two former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
The Indiana Clinical and Translational Sciences Institute awarded $750,000 to 10 teams of researchers.
Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
David Stocum is the director of the Center for Regenerative Biology and Medicine at the IUPUI School of Science.
He and his team are studying how amphibians regenerate parts of their bodies to see if there are ways to induce humans to
regenerate tissue that is lost or damaged. The center has about 20 researchers and funding of about $14 million to fuel its
quest.
The drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
Former collaborator alleges firm breached its agreement with him and refused to pay royalty income.
Bloomington led the nation as the No. 1 small city in medical devices and equipment.
The university is hoping to find a private company to take over the 5-year-old facility, which formulated and manufactured
small batches of drugs used in clinical trials.
Indianapolis-based health insurer trades jabs with U.S. health secretary after Reuters story claims insurer deliberately cancels
coverage for breast cancer patients.
The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
The upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought
aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo Inc. bring its artery-measurement
product to market as soon as 2011.
Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.
Indiana University, which has received nearly $600 million from the endowment over the last three decades, will leverage the
new gift to increase its
scientific discoveries and commercialize life science innovations.
FAST Diagnostics LLC said initial human trials on its method to measure kidney function faster and more accurately than existing
techniques could begin as early as next year, with commercialization following by 2012.
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
Previous gifts from the foundation to the cancer center have been used to hire 10 researchers working on breast cancer.
